At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 140 enrolled
Drug / intervention
sufentanil sublingual tablet 30 mcgdrug
Likely dose
sufentanil sublingual tablet 30 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain
In Brief
A Phase 3 clinical trial evaluating sufentanil sublingual tablet 30 mcg for Acute Moderate-to-severe Pain. Completed, enrolled 140 participants across 2 sites.
Detailed Summary
This is a multicenter, open-label study in patients 40 years and older who are undergoing a surgical procedure. Patients may receive one dose of ST 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Moderate-to-severe Pain
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartMar 2016
Primary CompletionJun 2016
Study CompletionJul 2016
TodayJul 2026
First PostedJan 25, 2016
Enrollment StartMar 1, 2016
Primary CompletionJun 1, 2016
Study CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 10.4 years ago
Interventions
sufentanil sublingual tablet 30 mcgdrug
sufentanil sublingual tablet 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.